Biggest News Aggregation in the World
📰 Eric Crombez News

Eric Crombez News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Eric Crombez. Real-time updates on events, politics, business and more.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript February 15, 2024 Ultragenyx Pharmaceutical Inc. beats earnings expectations. Reported EPS is $-1.52, expectations were $-1.65. Ultragenyx Pharmaceutical Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
New York United States Gena Wang Howard Horn Emil Kakkis Eric Crombez
Source: yahoo.com

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024 NOVATO, Calif., Jan. 25, 2024 --...
Carolyn Wang Eric Crombez Joshua Higa Drug Administration Ultragenyx Pharmaceutical Inc Exchange Commission

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript November 2, 2023 Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.23 EPS, expectations were $-2.08. Operator: Good afternoon, and welcome to the Ultragenyx Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end […]
United States Eric Crombez Elizabeth Barry Kravis Emil Kakkis Barry Kravis Kyowa Kirin
Source: yahoo.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density...
City Of United Kingdom British Columbia United States Jeff Blake Lee Roth

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science